Highly awaited Alzheimer's drug hit by delays
Eli Lilly's highly anticipated Alzheimer's drug has been held back for further review by regulators, the US pharmaceutical giant said Friday, in a blow for patients with the devastating brain disorder.
Mar 8, 2024
0
10